Surface Oncology, Inc.

Symbol: SURF

NASDAQ

1.07

USD

Market price today

  • -0.6911

    P/E Ratio

  • 0.0043

    PEG Ratio

  • 65.08M

    MRK Cap

  • 0.00%

    DIV Yield

Surface Oncology, Inc. (SURF) Financial Statements

On the chart you can see the default numbers in dynamics for Surface Oncology, Inc. (SURF). Companys revenue shows the average of 36.155 M which is 2.889 % gowth. The average gross profit for the whole period is 36.155 M which is 2.889 %. The average gross profit ratio is 1.000 %. The net income growth for the company last year performance is -0.178 % which equals -1.117 % % on average for the whole company history.,

Balance Sheet

Diving into the fiscal trajectory of Surface Oncology, Inc., we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to 0. A look back at the past year reveals a total asset change of -0.162. In the realm of current assets, SURF clocks in at 129.14 in the reporting currency. A significant portion of these assets, precisely 124.823, is held in cash and short-term investments. This segment shows a change of -0.190% when juxtaposed with last year's data. Long-term investments of the company, while not its focus, stand at 0, if any, in the reporting currency. This indicates a difference of 0.000% from the last reporting period, reflecting the company's strategic shifts. The debt profile of the company shows a total long-term debt of 50.247 in the reporting currency. This figure signifies a year_over_year change of -0.022%. Shareholder value, as depicted by the total shareholder equity, is valued at 93.403 in the reporting currency. The year over year change in this aspect is -0.214%. Account payables and short-term debt are 0.26 and 5.79, respectively. The total debt is 56.04, with a net debt of 5.13. Other current liabilities amount to 10.21, adding to the total liabilities of 66.51. Lastly, the referred stock is valued at 0, if it exists.

common:word.in-mln

USD
Growth
TTM2022202120202019201820172016

balance-sheet.row.cash-and-short-term-investments

429.49124.8154.1175.1
105.2
158.8
63.3
79.2

balance-sheet.row.short-term-investments

269.6673.998.10
58.4
75.9
40.9
69.2

balance-sheet.row.net-receivables

0.20.20.82.6
0.3
0.3
0.3
5.4

balance-sheet.row.inventory

-0.2-0.2-0.8-2.6
-0.3
0
0
0

balance-sheet.row.other-current-assets

17.574.33.25.4
2.8
5.4
0
0

balance-sheet.row.total-current-assets

447.06129.1157.3180.5
107.9
164.6
71.3
93.2

balance-sheet.row.property-plant-equipment-net

92.6129.231.534.6
22.1
8.2
7.3
3.9

balance-sheet.row.goodwill

0000
0
0
0
0

balance-sheet.row.intangible-assets

0000
0
0
0
0

balance-sheet.row.goodwill-and-intangible-assets

0000
0
0
0
0

balance-sheet.row.long-term-investments

0000
0
0
0
0

balance-sheet.row.tax-assets

0000
0
0
0
0

balance-sheet.row.other-non-current-assets

4.881.622.1
1.6
1.2
2.8
1.1

balance-sheet.row.total-non-current-assets

97.4930.833.536.6
23.8
9.5
10.1
5

balance-sheet.row.other-assets

0000
0
0
0
0

balance-sheet.row.total-assets

544.54159.9190.8217.1
131.7
174.1
81.5
98.1

balance-sheet.row.account-payables

2.510.31.61.7
3.4
3.4
3.2
2.8

balance-sheet.row.short-term-debt

30.075.85.45.5
3
-30.7
9.8
6.5

balance-sheet.row.tax-payables

0000
0
0
0
0

balance-sheet.row.long-term-debt-total

147.4850.251.943.7
22.1
0
0
0

Deferred Revenue Non Current

0000
33.7
54
72.3
58.1

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-

balance-sheet.row.other-current-liab

33.2610.23.21
-25.7
0.5
10.3
6.6

balance-sheet.row.total-non-current-liabilities

147.4850.251.943.7
55.8
44
76.9
60.4

balance-sheet.row.other-liabilities

0000
0
0
0
0

balance-sheet.row.capital-lease-obligations

100.830.532.334.5
19.9
0
0
0

balance-sheet.row.total-liab

213.3166.571.961.4
75
71.2
100.3
76.6

balance-sheet.row.preferred-stock

0000
0
174.1
0
48.5

balance-sheet.row.common-stock

0.02000
0
0
0
0

balance-sheet.row.retained-earnings

-863.66-204.3-140.7-62.3
-121.6
-66.8
-73.9
-28.6

balance-sheet.row.accumulated-other-comprehensive-income-loss

-3.17-1-0.20
0.1
-0.1
-0.2
-0.4

balance-sheet.row.other-total-stockholders-equity

1198.04298.7259.9218
178.2
-4.3
55.4
2

balance-sheet.row.total-stockholders-equity

331.2393.4118.9155.7
56.7
102.9
-18.8
21.6

balance-sheet.row.total-liabilities-and-stockholders-equity

544.54159.9190.8217.1
131.7
174.1
81.5
98.1

balance-sheet.row.minority-interest

0000
0
0
0
0

balance-sheet.row.total-equity

331.2393.4118.9155.7
56.7
102.9
-18.8
21.6

balance-sheet.row.total-liabilities-and-total-equity

544.54---
-
-
-
-

Total Investments

269.6673.998.10
58.4
75.9
40.9
69.2

balance-sheet.row.total-debt

177.555657.349.3
25
0
0
0

balance-sheet.row.net-debt

17.725.11.3-125.9
-21.7
-158.8
-22.5
-10

Cash Flow Statement

The financial landscape of Surface Oncology, Inc. has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of 0.039. The company recently extended its share capital by issuing 31.38, marking a difference of 20.000 compared to the previous year. The company's investing activities resulted in net cash usage, amounting to 22757000.000 in the reporting currency. This is a shift of -1.229 from the previous year. In the same period, the company recorded 1.37, 0, and 0, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of 0.000, with a year over year difference of 0.000. Furthermore, the company allocated 0 for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as 0.28, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM2022202120202019201820172016

cash-flows.row.net-income

-92.5-63.6-78.559.3
-54.8
-6.6
-45.4
-17.5

cash-flows.row.depreciation-and-amortization

2.981.41.61.7
1.8
1.3
1
0.3

cash-flows.row.deferred-income-tax

-0.1100.80
-0.8
0
0
0

cash-flows.row.stock-based-compensation

6.127.28.57.8
6
5.2
4.7
1.3

cash-flows.row.change-in-working-capital

-5.8-7.62.1-42.3
-14.3
-12.8
26.7
58.6

cash-flows.row.account-receivables

0000
0
0
0
0

cash-flows.row.inventory

0000
0
0
0
0

cash-flows.row.account-payables

0.18-1.3-0.2-2.7
0.6
0
0.3
1.8

cash-flows.row.other-working-capital

0.29-6.32.3-39.6
-14.8
-12.8
26.4
56.8

cash-flows.row.other-non-cash-items

5.7333.13.6
1.9
-0.4
0.6
-1.4

cash-flows.row.net-cash-provided-by-operating-activities

-83.58000
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-0.35-0.5-0.10
-1.5
-2
-2
-0.8

cash-flows.row.acquisitions-net

0000
-17
36.6
0
0

cash-flows.row.purchases-of-investments

-60.07-40.2-111.6-0.7
-118.3
-107.3
0
-97

cash-flows.row.sales-maturities-of-investments

101.7763.412.559
136.8
72.7
27.9
28.9

cash-flows.row.other-investing-activites

0000
17
-36.6
0
0

cash-flows.row.net-cash-used-for-investing-activites

41.3522.8-99.358.3
17
-36.6
25.9
-69

cash-flows.row.debt-repayment

0000
0
0
0
0

cash-flows.row.common-stock-issued

8.7131.429.529.1
0
111.9
0
0

cash-flows.row.common-stock-repurchased

0000
0
0
0
0

cash-flows.row.dividends-paid

0000
0
0
0
0

cash-flows.row.other-financing-activites

0.190.31311
7.4
-1.6
-1
0

cash-flows.row.net-cash-used-provided-by-financing-activities

-19.3531.742.540.1
7.4
110.4
-1
25.9

cash-flows.row.effect-of-forex-changes-on-cash

0000
0
0
0
0

cash-flows.row.net-change-in-cash

-61.58-5.1-119.1128.4
-35.8
60.6
12.5
-1.6

cash-flows.row.cash-at-end-of-period

164.6252.557.6176.7
48.4
84.1
22.5
11.1

cash-flows.row.cash-at-beginning-of-period

226.1957.6176.748.4
84.1
23.5
10
12.7

cash-flows.row.operating-cash-flow

-83.58-59.6-62.330
-60.1
-13.2
-12.4
41.4

cash-flows.row.capital-expenditure

-0.35-0.5-0.10
-1.5
-2
-2
-0.8

cash-flows.row.free-cash-flow

-83.93-60-62.530
-61.7
-15.2
-14.4
40.6

Income Statement Row

Surface Oncology, Inc.'s revenue saw a change of 10.165% compared with the previous period. The gross profit of SURF is reported to be 30. The company's operating expenses are 91.87, showing a change of 16.733% from the last year. The expenses for depreciation and amortization are 1.37, which is a -0.128% change from the last accounting period. Operating expenses are reported to be 91.87, which shows a 16.733% year-over-year change. Selling and marketing expenses are 0, which is a 0.000% change compared to the previous year. The EBITDA based on the recent numbers is 0, representing a 0.186% year-over-year growth. The operating income is -61.87, which shows a -0.186% change when compared to the previous year. The change in the net income is -0.178%. The net income for the last year was -65.3.

common:word.in-mln

USD
Growth
TTM2022202120202019201820172016

income-statement-row.row.total-revenue

30302.7126.2
15.4
59.4
12.8
6.6

income-statement-row.row.cost-of-revenue

0000
0
0
0
0

income-statement-row.row.gross-profit

30302.7126.2
15.4
59.4
12.8
6.6

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0

income-statement-row.row.research-development

59.79---
-
-
-
-

income-statement-row.row.selling-general-administrative

26.36---
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-

income-statement-row.row.other-expenses

2.651.40.10
2.6
2.6
0
0

income-statement-row.row.operating-expenses

86.1591.978.764.6
72.7
68.6
58.8
24.6

income-statement-row.row.cost-and-expenses

86.1591.978.764.6
72.7
68.6
58.8
24.6

income-statement-row.row.interest-income

0000
2.6
2.6
0.6
0.6

income-statement-row.row.interest-expense

5.021.72.52.2
0
0
0
0

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-

income-statement-row.row.total-other-income-expensenet

-3.25-1.7-2.5-2.2
2.6
2.6
0.6
0.6

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-

income-statement-row.row.other-operating-expenses

2.651.40.10
2.6
2.6
0
0

income-statement-row.row.total-operating-expenses

-3.25-1.7-2.5-2.2
2.6
2.6
0.6
0.6

income-statement-row.row.interest-expense

5.021.72.52.2
0
0
0
0

income-statement-row.row.depreciation-and-amortization

4.331.41.61.7
1.8
1.3
1
0.3

income-statement-row.row.ebitda-caps

-81.6---
-
-
-
-

income-statement-row.row.operating-income

-89.39-61.9-7661.6
-57.4
-9.2
-46
-18

income-statement-row.row.income-before-tax

-92.51-63.6-78.559.3
-54.8
-6.6
-45.4
-17.5

income-statement-row.row.income-tax-expense

5.171.710.6
-1.8
2.6
0
0

income-statement-row.row.net-income

-94.01-65.3-79.559.3
-53
-6.6
-45.4
-17.5

Frequently Asked Question

What is Surface Oncology, Inc. (SURF) total assets?

Surface Oncology, Inc. (SURF) total assets is 159910000.000.

What is enterprise annual revenue?

The annual revenue is N/A.

What is firm profit margin?

Firm profit margin is 1.000.

What is company free cash flow?

The free cash flow is -1.382.

What is enterprise net profit margin?

The net profit margin is -3.134.

What is firm total revenue?

The total revenue is -2.980.

What is Surface Oncology, Inc. (SURF) net profit (net income)?

The net profit (net income) is -65303000.000.

What is firm total debt?

The total debt is 56037000.000.

What is operating expences number?

The operating expences are 91869000.000.

What is company cash figure?

Enretprise cash is 14842000.000.